Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

59.48 -1.62 (-2.65%)

Streaming Delayed Price Updated: 2:33 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

88 89 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

March 11, 2025

Via Benzinga

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal ↗

March 11, 2025

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.

Via Benzinga

US Stocks Likely To Open Higher After Monday's Selloff: TSLA Stock Rebounds From Its Worst Fall In 5 Years After Trump Backs Musk, Analyst Says 'Pullbacks Are Normal' ↗

March 11, 2025

U.S. stock futures rose on Tuesday following Monday's heavy selloff. Futures of all four benchmark indices surged in premarket trading.

Via Benzinga

Topics Government

Which S&P500 stocks are moving on Monday? ↗

March 10, 2025

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Market Whales and Their Recent Bets on BMY Options ↗

March 07, 2025

Via Benzinga

How Is The Market Feeling About Bristol-Myers Squibb? ↗

March 06, 2025

Via Benzinga

Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis ↗

March 10, 2025

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

Via Benzinga

Why Is Protagonist Therapeutics Stock Trading Higher On Monday? ↗

March 10, 2025

Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.

Via Benzinga

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out ↗

March 10, 2025

The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment.

Via Investor's Business Daily

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

March 10, 2025

Via Benzinga

Healthcare Sector Trying To Bounce Back ↗

March 09, 2025

I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.

Via Talk Markets

Topics ETFs Stocks / Equities

Is NYSE:BMY suited for dividend investing? ↗

February 25, 2025

Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential.

Via Chartmill

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

March 08, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers' Opdivo Plus Yervoy Combo Therapy Secures European Approval For Untreated Liver Cancer Patients ↗

March 07, 2025

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant overall survival benefits.

Via Benzinga

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

March 07, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal ↗

March 05, 2025

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

Via Benzinga

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

March 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Dividend

March 03, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q4 Earnings?

February 28, 2025

Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, representing a healthy 18.8% increase. This run-up might have...

Via StockStory

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

February 27, 2025

Via Benzinga

Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗

February 26, 2025

Via The Motley Fool

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

February 25, 2025

From Bristol Myers Squibb

Via Business Wire

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 24, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

February 24, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Via Chartmill

Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review ↗

February 24, 2025

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a decision expected by June 2025.

Via Benzinga

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

February 24, 2025

From Bristol Myers Squibb

Via Business Wire

NYSE:BMY: good value for what you're paying. ↗

February 24, 2025

BRISTOL-MYERS SQUIBB CO has a stellar value proposition. NYSE:BMY not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? ↗

February 21, 2025

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.

Via Benzinga

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

88 89 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.